{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T07:15:36Z","timestamp":1792826136604,"version":"4.5.0"},"reference-count":131,"publisher":"SAGE Publications","issue":"7","license":[{"start":{"date-parts":[[2024,9,26]],"date-time":"2024-09-26T00:00:00Z","timestamp":1727308800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Parkinson\u2019s Disease"],"published-print":{"date-parts":[[2024,10,15]]},"abstract":"<jats:p>\u00a0Inflammation and immune dysregulation have been linked to the pathogenesis and progression of Parkinson\u2019s disease (PD), and represent an attractive target for therapeutic intervention, given the potential for repurposing of existing anti-inflammatory and immunomodulatory agents. Despite the fact that initial studies of drugs with secondary anti-inflammatory effects did not yield positive results, agents specifically targeting immune and inflammatory pathways may hold more promise. This article will briefly review the evidence base for targeting the immune system and neuroinflammation in PD, and discuss in detail the recently completed and currently active trials of primary anti-inflammatory\/immunomodulatory drugs in PD.<\/jats:p>","DOI":"10.3233\/jpd-240353","type":"journal-article","created":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T10:27:34Z","timestamp":1727432854000},"page":"1283-1300","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":17,"title":["Clinical Trial Highlights: Anti-Inflammatory and Immunomodulatory Agents"],"prefix":"10.1177","volume":"14","author":[{"given":"Bina","family":"Patel","sequence":"first","affiliation":[{"name":"John van Geest Centre for Brain Repair, Department of Clinical Neurosciences, University of Cambridge, Forvie Site, Robinson Way, Cambridge CB2 0PY, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia C.","family":"Greenland","sequence":"additional","affiliation":[{"name":"John van Geest Centre for Brain Repair, Department of Clinical Neurosciences, University of Cambridge, Forvie Site, Robinson Way, Cambridge CB2 0PY, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline H.","family":"Williams-Gray","sequence":"additional","affiliation":[{"name":"John van Geest Centre for Brain Repair, Department of Clinical Neurosciences, University of Cambridge, Forvie Site, Robinson Way, Cambridge CB2 0PY, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2024,9,26]]},"reference":[{"key":"ref001","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2013-305277"},{"key":"ref002","doi-asserted-by":"publisher","DOI":"10.1016\/S1353-8020(11)70065-7"},{"key":"ref003","doi-asserted-by":"publisher","DOI":"10.1186\/s40035-015-0042-0"},{"key":"ref004","doi-asserted-by":"publisher","DOI":"10.3390\/cells11182908"},{"key":"ref005","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.38.8.1285"},{"key":"ref006","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-021-10877-z"},{"key":"ref007","doi-asserted-by":"publisher","DOI":"10.1002\/ana.20338"},{"key":"ref008","doi-asserted-by":"publisher","DOI":"10.1002\/mds.29363"},{"key":"ref009","doi-asserted-by":"publisher","DOI":"10.1186\/s40478-020-01083-5"},{"key":"ref010","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a009373"},{"key":"ref011","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2008.05.002"},{"key":"ref012","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2019.577089"},{"key":"ref013","doi-asserted-by":"publisher","DOI":"10.1038\/s41531-018-0061-5"},{"key":"ref014","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.2100035"},{"key":"ref015","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0055375"},{"key":"ref016","doi-asserted-by":"publisher","DOI":"10.3233\/JPD-223338"},{"key":"ref017","doi-asserted-by":"publisher","DOI":"10.1002\/mds.26563"},{"key":"ref018","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2016.2742"},{"key":"ref019","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2018.00234"},{"key":"ref020","doi-asserted-by":"publisher","DOI":"10.1002\/mds.29369"},{"key":"ref021","doi-asserted-by":"publisher","DOI":"10.1002\/mds.28685"},{"key":"ref022","doi-asserted-by":"publisher","DOI":"10.3892\/mmr.2015.4136"},{"key":"ref023","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-018-1206-5"},{"key":"ref024","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-021-02287-9"},{"key":"ref025","doi-asserted-by":"publisher","DOI":"10.1016\/j.tins.2023.07.005"},{"key":"ref026","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000001036"},{"key":"ref027","doi-asserted-by":"publisher","DOI":"10.1007\/s11481-012-9402-z"},{"key":"ref028","doi-asserted-by":"publisher","DOI":"10.1038\/nature22815"},{"key":"ref029","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-15626-w"},{"key":"ref030","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-019-1606-1"},{"key":"ref031","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-018-1248-8"},{"key":"ref032","doi-asserted-by":"publisher","DOI":"10.1093\/braincomms\/fcad060"},{"key":"ref033","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbi.2022.01.005"},{"key":"ref034","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2023.578154"},{"key":"ref035","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbi.2020.01.018"},{"key":"ref036","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-014-1345-4"},{"key":"ref037","doi-asserted-by":"publisher","DOI":"10.1016\/j.stem.2018.06.015"},{"key":"ref038","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awab103"},{"key":"ref039","first-page":"182","volume":"119","author":"Brochard V","year":"2009","journal-title":"J Clin Invest"},{"key":"ref040","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2017.11.010"},{"key":"ref041","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.369"},{"key":"ref042","doi-asserted-by":"publisher","DOI":"10.3233\/JPD-223176"},{"key":"ref043","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2020.00193"},{"key":"ref044","doi-asserted-by":"publisher","DOI":"10.1159\/000333222"},{"key":"ref045","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2018.0605"},{"key":"ref046","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e31820f2d79"},{"key":"ref047","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.580"},{"key":"ref048","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3181d5a4a3"},{"key":"ref049","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.95.26.15769"},{"key":"ref050","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.166.12.7527"},{"key":"ref051","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.251341998"},{"key":"ref052","doi-asserted-by":"publisher","DOI":"10.1097\/WNF.0b013e3181342f32"},{"key":"ref053","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000201252.57661.e1"},{"key":"ref054","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1989.00520460028009"},{"key":"ref055","doi-asserted-by":"publisher","DOI":"10.1186\/1742-2094-8-91"},{"key":"ref056","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2004.12.015"},{"key":"ref057","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(15)00144-1"},{"key":"ref058","doi-asserted-by":"publisher","DOI":"10.3233\/JPD-150666"},{"key":"ref059","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2017.09.023"},{"key":"ref060","doi-asserted-by":"publisher","DOI":"10.1677\/JOE-09-0132"},{"key":"ref061","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31585-4"},{"key":"ref062","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-047993"},{"key":"ref063","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2312323"},{"key":"ref064","doi-asserted-by":"publisher","DOI":"10.3233\/JPD-171203"},{"key":"ref065","unstructured":"CaroleC. PD STAT study findings: Simvastatin as a neuroprotective treatment for Parkinson\u2019s disease \u2013 a double-blind, placebo controlled clinical learning study in patients of moderate severity. https:\/\/www.plymouth.ac.uk\/research\/penctu\/pd-stat-study-findings"},{"key":"ref066","doi-asserted-by":"publisher","DOI":"10.1002\/mds.28474"},{"key":"ref067","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.3018-19.2021"},{"key":"ref068","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M200250200"},{"key":"ref069","doi-asserted-by":"publisher","DOI":"10.1007\/s11064-012-0781-6"},{"key":"ref070","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-018-3592-y"},{"key":"ref071","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbi.2019.06.042"},{"key":"ref072","doi-asserted-by":"publisher","DOI":"10.1007\/s11011-023-01254-y"},{"key":"ref073","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20184559"},{"key":"ref074","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines9121881"},{"key":"ref075","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21228637"},{"key":"ref076","doi-asserted-by":"publisher","DOI":"10.1089\/ars.2010.3731"},{"key":"ref077","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-040527"},{"key":"ref078","doi-asserted-by":"publisher","DOI":"10.1038\/s41531-017-0013-5"},{"key":"ref079","doi-asserted-by":"publisher","DOI":"10.1186\/s40035-023-00361-1"},{"key":"ref080","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2021.103380"},{"key":"ref081","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-020-00877-8"},{"key":"ref082","doi-asserted-by":"publisher","DOI":"10.1016\/j.neulet.2018.05.052"},{"key":"ref083","doi-asserted-by":"publisher","DOI":"10.1097\/WNR.0000000000000740"},{"key":"ref084","unstructured":"IntelGenx Technologies Corp. IntelGenx Receives Approval to Conduct \u2018MONTPARK\u2019 Montelukast VersaFilm\n                      \u00ae\n                      Phase 2 Clinical Trial in Patients with Parkinson\u2019s Disease. \nhttps:\/\/www.globenewswire.com\/news-release\/2023\/11\/14\/2779952\/0\/en\/IntelGenx-Receives-Approval-to-Conduct-MONTPARK-Montelukast-VersaFilm-Phase-2-Clinical-Trial-in-Patients-with-Parkinson-s-Disease.html"},{"key":"ref085","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.00668.2009"},{"issue":"1","key":"ref086","volume":"38","author":"Aldred J","year":"2023","journal-title":"Mov Disord"},{"key":"ref087","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)65542-3"},{"key":"ref088","doi-asserted-by":"publisher","DOI":"10.1038\/s42003-023-04665-w"},{"key":"ref089","unstructured":"ClinicalTrials.gov. Study Assessing Efficacy and Safety of AKST4290 in Subjects With Parkinson\u2019s Disease on Stable Dopaminergic Treatment (TEAL). https:\/\/classic.clinicaltrials.gov\/ct2\/show\/results\/NCT04369430"},{"key":"ref090","unstructured":"Press Release: Nod Thera. NodThera\u2019s NLRP3 Inhibitor NT-0796 Reverses Neuroinflammation in Parkinson\u2019s Disease Phase Ib\/IIa Trial. https:\/\/www.nodthera.com\/news\/nodtheras-nlrp3-inhibitor-nt-0796-reverses-neuro-inflammation-in-parkinsons-disease-phase-ib-iia-trial\/#"},{"key":"ref091","unstructured":"Cambridge University NHS Trust. Drug trial brings hope to Parkinson\u2019s patients. https:\/\/www.cuh.nhs.uk\/news\/drug-trial-brings-hope-to-parkinsons-patients\/"},{"key":"ref092","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-023-02830-w"},{"key":"ref093","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1716095115"},{"key":"ref094","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(20)30065-5"},{"key":"ref095","doi-asserted-by":"publisher","DOI":"10.1097\/FJC.0000000000000931"},{"key":"ref096","unstructured":"News Release: Ventyx Biosciences Inc. Ventyx Biosciences Reports Clinical Data for its NLRP3 Inhibitor Portfolio and Provides Pipeline Updates at Virtual Investor Event. https:\/\/ir.ventyxbio.com\/news-releases\/news-release-details\/ventyx-biosciences-reports-clinical-data-its-nlrp3-inhibitor"},{"key":"ref097","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.1162"},{"key":"ref098","unstructured":"Zydus Lifesciences Limited. Zydus receives approval from USFDA to initiate Phase II clinical trial of ZYIL1 in patients with Parkinson\u2019s disease. https:\/\/www.zyduslife.com\/investor\/admin\/uploads\/21\/83\/Zydus-receives-approval-from-USFDA-to-initiate-Phase-II-clinical-trial-of-ZYIL1-in-patients-with-Parkinson-s-disease.pdf"},{"key":"ref099","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2019.05.011"},{"key":"ref100","first-page":"CD003982","volume":"2007","author":"Casetta I","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"key":"ref101","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v23.i18.3240"},{"key":"ref102","doi-asserted-by":"publisher","DOI":"10.3233\/JPD-2011-0002"},{"key":"ref103","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2005.07.005"},{"key":"ref104","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2011.02.011"},{"key":"ref105","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2013.10.009"},{"key":"ref106","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2018.00815"},{"key":"ref107","doi-asserted-by":"publisher","DOI":"10.1126\/science.6301011"},{"key":"ref108","first-page":"52","volume":"42","author":"Wang H","year":"2013","journal-title":"Zhejiang Da Xue Xue Bao Yi Xue Ban"},{"key":"ref109","doi-asserted-by":"publisher","DOI":"10.1016\/j.taap.2018.09.012"},{"key":"ref110","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroscience.2012.10.009"},{"key":"ref111","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2013.06.014"},{"key":"ref112","first-page":"969418","volume":"2012","author":"Nicoletti F","year":"2012","journal-title":"Parkinsons Dis"},{"key":"ref113","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamcr.2010.12.012"},{"key":"ref114","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)64487-2"},{"key":"ref115","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1012071107"},{"issue":"1","key":"ref116","volume":"38","author":"Philippens I","year":"2023","journal-title":"Mov Disord"},{"key":"ref117","doi-asserted-by":"publisher","DOI":"10.1016\/j.dadm.2016.05.004"},{"key":"ref118","first-page":"277","volume":"15","author":"Targowski T","year":"2005","journal-title":"J Investig Allergol Clin Immunol"},{"key":"ref119","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbi.2013.07.007"},{"key":"ref120","doi-asserted-by":"publisher","DOI":"10.1159\/000323779"},{"key":"ref121","doi-asserted-by":"publisher","DOI":"10.1007\/s13760-018-01061-8"},{"key":"ref122","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M116.714824"},{"key":"ref123","doi-asserted-by":"publisher","DOI":"10.1007\/s12035-020-02198-5"},{"key":"ref124","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aah4066"},{"key":"ref125","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-019-1670-6"},{"key":"ref126","doi-asserted-by":"publisher","DOI":"10.1038\/s41531-020-00147-6"},{"key":"ref127","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.1471"},{"key":"ref128","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.3c01398"},{"key":"ref129","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.123.002013"},{"key":"ref130","author":"Clarke N","journal-title":"Therapeutic Interventions in AD and PD"},{"key":"ref131","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.1318"}],"container-title":["Journal of Parkinson\u2019s Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.3233\/JPD-240353","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.3233\/JPD-240353","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.3233\/JPD-240353","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T04:53:59Z","timestamp":1777611239000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.3233\/JPD-240353"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,26]]},"references-count":131,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,10,15]]}},"alternative-id":["10.3233\/JPD-240353"],"URL":"https:\/\/doi.org\/10.3233\/jpd-240353","relation":{},"ISSN":["1877-7171","1877-718X"],"issn-type":[{"value":"1877-7171","type":"print"},{"value":"1877-718X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,26]]}}}